Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Exagen Inc.

Market Cap 105M 92.43M 85.17M 79.73M 149M 9.97B 152M 1.02B 396M 4.89B 395M 386M 17B P/E 2026 *
-6.31x
P/E 2027 * -8.6x
Enterprise Value 105M 92.43M 85.17M 79.73M 149M 9.97B 152M 1.02B 396M 4.89B 395M 386M 17B EV / Sales 2026 *
1.47x
EV / Sales 2027 * 1.33x
Free-Float
57.25%
Yield 2026 *
-
Yield 2027 * -
1 day+2.99%
1 week+6.00%
Current month-9.54%
1 month-2.49%
3 months+64.42%
6 months-27.22%
Current year-25.90%
1 week 4.23
Extreme 4.23
4.67
1 month 4.11
Extreme 4.11
5.55
Current year 2.59
Extreme 2.59
6.75
1 year 2.59
Extreme 2.59
12.23
3 years 1.3
Extreme 1.3003
12.23
5 years 1.3
Extreme 1.3003
16.48
10 years 1.3
Extreme 1.3003
29.86
Manager TitleAgeSince
Chief Executive Officer 41 2022-10-16
Director of Finance/CFO 57 2024-08-31
Chief Tech/Sci/R&D Officer - 2025-06-22
Director TitleAgeSince
Director/Board Member 63 2019-07-29
Director/Board Member 58 2023-07-23
Director/Board Member 66 2024-06-09
Date Insider Type Main position Quantity % Market Cap.
06-08Free

Director

37,500 0.1552%
06-08Free

Director

37,500 0.1552%
06-08Free

Director

37,500 0.1552%
Change 5-day change 1-year change 3-year change Capi.($)
+2.99%+6.00%-36.19%+52.20% 105M
+7.99%+12.08%+47.67%+409.13% 33.62B
+2.26%+1.99%+0.83%+12.08% 21.2B
+0.15%-0.10%-24.20%-42.78% 6.79B
+1.21%+7.50%+1.79%+73.32% 4.42B
-0.57%+0.50%+21.29%+53.24% 2.95B
-1.22%+5.21%+39.20%-25.88% 1.75B
-1.38%-0.12%-12.97%-67.06% 1.66B
+7.89%+10.17%-31.62%+966.21% 1.72B
-1.18%+2.31%+14.12%-4.69% 1.58B
Average +1.82%+0.31%+1.99%+142.58% 7.58B
Weighted average by Cap. +4.34%+2.37%+20.29%+207.28%

Financials

2026 *2027 *
Net sales 71.58M 62.89M 57.95M 54.24M 102M 6.78B 103M 696M 269M 3.33B 269M 263M 11.56B 79.37M 69.72M 64.25M 60.14M 113M 7.52B 115M 771M 299M 3.69B 298M 292M 12.82B
Net income -16.59M -14.58M -13.43M -12.57M -23.56M -1.57B -23.96M -161M -62.43M -771M -62.29M -60.95M -2.68B -12.38M -10.87M -10.02M -9.38M -17.57M -1.17B -17.87M -120M -46.57M -575M -46.46M -45.46M -2B
Net Debt - -
Logo Exagen Inc.
Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.
Employees
218
Date Price Change Volume
26-06-24 US$4.505 +3.44% 16,169
26-06-23 US$4.355 -1.47% 104,156
26-06-22 US$4.420 -2.64% 258,689
26-06-18 US$4.540 +6.82% 304,684
26-06-17 US$4.250 -6.59% 436,514
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.355USD
Average target price
8.667USD
Spread / Average Target
+99.01%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!